Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The cognitive and related symptoms of Alzheimer's disease are mainly attributable to synaptic failure. Here we review recent research on how the Alzheimer's disease amyloid ß-protein (Aß) affects glutamate receptors and fast excitatory synaptic transmission and plasticity of that transmission. l-glutamate, the main excitatory neurotransmitter in the brain, has long been implicated in causing NMDA receptor-mediated excitotoxicity leading to neurodegeneration in the late stages of the disease. However there is now extensive evidence that soluble Aß oligomers disrupt synaptic transmission and especially synaptic plasticity via non-excitotoxic glutamatergic mechanisms. New data highlight the relatively selective involvement of certain glutamate receptor subtypes including GluN2B (NR2B) subunit-containing NMDA receptors and mGlu5 receptors. Aß exerts direct and indirect effects on synaptic plasticity-related glutamate receptor signaling and trafficking between different neuronal compartments. For example, Aß-induced ectopic NMDA and mGlu receptor-mediated signaling coupled with caspase-3 activation may cause inhibition of long-term potentiation and facilitation of long-term depression. Intriguingly, some of the disruptive synaptic actions of Aß have been found to be dependent on endogenous tau located in dendrites or spines. Given the role of glutamatergic transmission in regulating Aß production and release, future therapies targeting glutamate offer the opportunity to remedy both mis-processing of Aß and cellular mechanisms of synaptic failure in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 2×
“Remarkably, although tau, the other key player in AD pathology, is normally considered to be principally involved in the stable assembly of microtubules, a key role in regulating the phosphorylation of GluN2B subunits by the Src kinase Fyn has been reported (Ittner et al., 2010).”
BackgroundAmyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 1×
“…related synaptic mechanisms in preclinical research on Alzheimer's disease (AD) and other neurodegenerative disorders have been published recently (Johnson et al. , 2009, Lau and Tymianski, 2010, Luscher and Huber, 2010, Ondrejcak et al. , 2010, Palop and Mucke, 2010a, b, Randall et al. , 2010).”
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · cited 2×
“Similarly, the relative importance of synaptic versus extrasynaptic glutamate receptors and their trafficking between different compartments in mediating Aß action needs to be integrated with our growing knowledge of their roles in cognitive decline in other neurodegenerative diseases such as Huntington’s disease (Har…”
Neural mechanisms of ageing and cognitive decline
Bishop, N. A., Lu, T., & Yankner, B. A. (2010) · Nature · doi:10.1038/nature08983 · Cited by 1,323 · cited 1×
“Such factors are likely to promote or trigger Aß and tau pathogenic mechanisms but may also interact as additive, independent causes of dementia (Bishop et al. , 2010, Pimplikar et al. , 2010).”
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Long-term depression in the CNS
Collingridge, G. L., Peineau, S., Howland, J. G., & Wang, Y. T. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2867 · Cited by 926
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Furthermore, prolonged exposure to soluble AD brain extracts that contain nanomolar Aß oligomers cause synaptic loss in a tau-dependent manner (Jin et al. , 2011).”
BackgroundMultimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · cited 1×
“AD is the main cause of dementia and can now be diagnosed years before clinically severe symptoms arise (Perrin et al. , 2009).”
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654 · cited 1×
“Furthermore, abnormal increased hippocampal excitatory synaptic transmission in hAPP transgenic mice is absent when these mice are crossed with taudeficient mice (Roberson et al. , 2011).”
Background
Cited by
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Excitotoxicity: Bridge to various triggers in neurodegenerative disorders
Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R., & Sharma, P. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.032 · Cited by 665
Schröder, N., Figueiredo, L. S., & de Lima, M. N. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121996 · Cited by 113
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Differentiation renders susceptibility to excitotoxicity in HT22 neurons
Suo, W., He, M., Liu, J., Cheng, S., & Xing, Y. (2013) · Neural Regeneration Research · doi:10.4103/1673-5374.121636 · Cited by 83
Metadata
- Authors
- Hu, N.-W., Ondrejcak, T., & Rowan, M. J.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 100
- Issue
- 4
- Pages
- 855-862
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2058412620
- Cited by
- 100
- References
- 26
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances. https://app.cochat.ai/papers/10.1016/j.pbb.2011.04.013
- The paper
- Hu, N.-W., Ondrejcak, T., & Rowan, M. J. (2012). Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2011.04.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.